This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
This is a global, Phase 3, randomized study of zanubrutinib versus ibrutinib in 652 participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
The primary efficacy endpoint is overall response rate determined by investigator assessment. Participants were randomized in a 1:1 manner to either zanubrutinib or ibrutinib. Treatment with zanubrutinib and ibrutinib was open label.
| Study Arm | Population | Intervention | Comparison | Outcome |
|---|---|---|---|---|
R/R CLL/SLL |
Zanubrutinib |
Ibrutinib |
Primary Endpoint: ORR Key Secondary Endpoints: PFS, OS, safety |
